Drug Trial Radar · NCT03680508
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Actual
Start
Dec 19, 2019
Primary completion
Mar 6, 2026
Study completion Oct 2027
Sponsor
- Lead sponsor
- University of HawaiiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GlaxoSmithKline
- First posted
- Sep 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to attack the cancer. This phase II trial is studying how well TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) work in combination in treating patients with locally advanced or metastatic liver cancer.
Conditions
- Adult Primary Liver Cancer
- Advanced Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
Interventions
TSR-022 and TSR-042Drug
immunotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: From date of treatment until the date of best documented response, assessed up to 36 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Hawaii
Honolulu, Hawaii
Oregon Health & Science University Knight Cancer Institute
Portland, Oregon
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.